Oncology Care Model Measure Specifications

OCM-8 NQF 0223 Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis to patients under the age of 80 with AJCC III (lymph node positive) colon cancer

Note: This version of the OCM-8 Measure Specifications is to be used for reporting beginning 07/01/2017 and future measurement periods. If an updated version of this document is released, this version will be used for reporting until the effective date of the new version.

Note: This specification should be used for submitting data through the data registry

SUMMARY OF CHANGES FROM NQF 0223 SPECIFICATIONS

- Timing added: Primary tumors of the colon must start during the 12 months before the end of the measurement period.
- Timing added: The clinical trial must start before the start of or during the measurement period and not end before the start of the measurement period.
- Timing added: Chemotherapy must be recommended and not received within 4 months (120 days) of diagnosis.

Description
Percentage of patients under the age of 80 with AJCC III (lymph node positive) colon cancer for whom adjuvant chemotherapy is recommended and not received or administered within 4 months (120 days) of diagnosis.

Measure Scoring
Proportion

Measure Type
Process

Improvement Notation
Higher score indicates better quality

Definitions
Not Applicable

Guidance
This measure is to be reported once per measurement period for qualifying patients.

Where available, FORDS equivalent NAACCR Items have been provided in the step instructions of the supplemental data elements and each population.
Oncology Care Model Measure Specifications

Chemotherapy recommended and not received:
1. Not recommended/administered because it was contraindicated due to patient risk factors.
2. Not administered because the patient died prior to planned or recommended therapy.
3. It was recommended by the patient’s physician but was not administered as part of the first course of therapy. No reason was stated in the patient record.
4. It was recommended by the patient’s physician but refused by the patient, patient’s family member, or the patient’s guardian. The refusal was noted in the patient record.

Supplemental Data Elements
For every patient evaluated by this measure also identify gender

<table>
<thead>
<tr>
<th>Step(s)</th>
<th>Instructions</th>
<th>Data Element(s)</th>
<th>OCM Code Set(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Step 1</td>
<td>For every patient evaluated by this measure identify gender</td>
<td>• Gender • NAACCR Item 220</td>
<td>• OCM Gender OR • NAACCR Item 220</td>
</tr>
</tbody>
</table>

(FORDS equivalent: NAACCR Item # 220)

Initial Population
Not Applicable

Denominator
Include, if all of the following characteristics are identified:
- Age 18-79 years at time of cancer diagnosis
- Known or assumed to be first or only cancer diagnosis
- Primary tumors of the colon starts during the 12 months before the end of the measurement period
- Colon Cancer treated surgically
- Epithelial invasive malignancy only
- At least one pathologically examined regional lymph node positive for cancer (AJCC Stage III)
- All or part of first course of treatment coordinated by the reporting practice

Note: For beneficiary-level reporting, cancer diagnosis and AJCC values reported for Staging and Clinical Data in the OCM Data Registry will be used.
<table>
<thead>
<tr>
<th>Step(s)</th>
<th>Instructions</th>
<th>Data Element(s)</th>
<th>OCM Code Set(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Step 1</strong></td>
<td>Age $\geq 18$ year(s) at time of colon cancer diagnosis &lt;br&gt; AND &lt;br&gt; Age $\leq 79$ year(s) at time of colon cancer diagnosis &lt;br&gt; (FORDS equivalent: &lt;br&gt; NAACCR Item # 230) &lt;br&gt; AND &lt;br&gt; Primary tumors of the colon starts during the 12 months before the end of the measurement period: &lt;br&gt; Note: NAACCR Items listed below may be used for practice-level aggregate reporting only. &lt;br&gt; NAACCR Item # 400 &lt;br&gt; NAACCR Item # 390</td>
<td>• Birthdate &lt;br&gt; • Colon Cancer Diagnosis &lt;br&gt; • Colon Cancer Diagnosis Start Date &lt;br&gt; • Measurement Period End Date &lt;br&gt; • NAACCR Item 230 &lt;br&gt; • NAACCR Item 400 &lt;br&gt; • NAACCR Item 390</td>
<td>• OCM Colon Cancer Diagnosis &lt;br&gt; OR &lt;br&gt; • NAACCR Item 230 &lt;br&gt; Additionally, for practice-level aggregate reporting: &lt;br&gt; • NAACCR Item 400 &lt;br&gt; • NAACCR Item 390</td>
</tr>
<tr>
<td><strong>Step 2</strong></td>
<td>First or only cancer diagnosis &lt;br&gt; Note: NAACCR Item listed below may be used for practice-level aggregate reporting only. &lt;br&gt; (FORDS equivalent: &lt;br&gt; NAACCR Item # 560)</td>
<td>• Colon Cancer Diagnosis &lt;br&gt; • Colon Cancer Diagnosis Start Date &lt;br&gt; • Other Cancer Diagnosis &lt;br&gt; • Other Cancer Diagnosis Start Date &lt;br&gt; • NAACCR Item 560</td>
<td>• OCM Colon Cancer Diagnosis &lt;br&gt; • OCM 8 Other Cancer Diagnosis &lt;br&gt; Additionally, for practice-level aggregate reporting: &lt;br&gt; • NAACCR Item 560</td>
</tr>
<tr>
<td><strong>Step 3</strong></td>
<td>Surgical treatment of the primary colon cancer site &lt;br&gt; (FORDS equivalent: &lt;br&gt; NAACCR Item # 1290)</td>
<td>• Colon Cancer Surgery &lt;br&gt; • Colon Cancer Surgery Date &lt;br&gt; • NAACCR Item 1290</td>
<td>• OCM Colon Cancer Surgery &lt;br&gt; OR &lt;br&gt; • NAACCR Item 1290</td>
</tr>
<tr>
<td><strong>Step 4</strong></td>
<td>Epithelial invasive malignancy only &lt;br&gt; (FORDS equivalent: &lt;br&gt; NAACCR Item # 522)</td>
<td>• Epithelial Malignancy &lt;br&gt; • NAACCR Item 522</td>
<td>• OCM 8 Epithelial Malignancy &lt;br&gt; OR &lt;br&gt; • NAACCR Item 522</td>
</tr>
<tr>
<td><strong>Step 5</strong></td>
<td>Behavior Code=Invasive: &lt;br&gt; NAACCR Item # 523</td>
<td>• NAACCR Item 523</td>
<td>• NAACCR Item 523</td>
</tr>
</tbody>
</table>
### Step(s) | Instructions | Data Element(s) | OCM Code Set(s)
---|---|---|---
Step 6 | At least one regional lymph node positive for cancer (AJCC Stage III)

Identify the valid TNM combinations using the following code sets:
OCM 8 T Values
OCM 8 N Values
OCM 8 M Values

Any combination of TNM values from the code sets listed above are allowed.

Note: Cancer stage and NAACCR Items listed below may be used for practice-level aggregate reporting only.

(FORDS equivalent:
NAACCR Item 820)

OR
Pathology Evaluation Stage III Results

- Pathology Evaluation
- OCM 8 T values
- OCM 8 N values
- OCM 8 M values
- Pathology Evaluation Result
- NAACCR Item 820

One code from each of the following:
- OCM 8 T values
- OCM 8 N values
- OCM 8 M values

Additionally, for practice-level aggregate reporting:

- OCM Pathology Evaluation

AND

One of the following options:
1. NAACCR Item 820

OR
2. OCM 8 Pathology Evaluation Stage III Results

Step 7 | All or part of first course of treatment coordinated by the reporting practice: NAACCR Item # 610 | NAACCR Item 610 | NAACCR Item 610

### Denominator Exclusions
Exclude, if any of the following characteristics are identified:
- In situ or metastatic disease (AJCC Stage IV)
- Patient died within 4 months (120 days) of diagnosis
- Patient participating in clinical trial which directly impacts receipt of standard of care after the colon cancer diagnosis
## Oncology Care Model Measure Specifications

<table>
<thead>
<tr>
<th>Step(s)</th>
<th>Instructions</th>
<th>Data Element(s)</th>
<th>OCM Code Set(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Step 1</strong></td>
<td>One of the following options:</td>
<td></td>
<td>One of the following options:</td>
</tr>
<tr>
<td>1.</td>
<td>Metastatic Disease (AJCC Stage IV):</td>
<td>Colon Cancer Diagnosis</td>
<td>1. NAACCR Item 910 Metastatic</td>
</tr>
<tr>
<td></td>
<td>NAACCR Item # 910 Metastatic</td>
<td>Colon Cancer Diagnosis Start Date</td>
<td>NAACCR Item 970 Metastatic</td>
</tr>
<tr>
<td></td>
<td>OR</td>
<td>Deceased</td>
<td>2. NAACCR Item 900 or 960</td>
</tr>
<tr>
<td>2.</td>
<td>Clinical M or Pathologic M:</td>
<td>Deceased Date</td>
<td>NAACCR Item 900</td>
</tr>
<tr>
<td></td>
<td>NAACCR Item # 900 or 960</td>
<td>Clinical Trial Participant</td>
<td>NAACCR Item 970 Metastatic</td>
</tr>
<tr>
<td>3.</td>
<td>In situ Disease:</td>
<td>Clinical Trial Participant Start Date</td>
<td>3. NAACCR Item 910 In Situ</td>
</tr>
<tr>
<td></td>
<td>NAACCR Item # 910 In Situ</td>
<td>Clinical Trial Participant End Date</td>
<td>NAACCR Item 970 In Situ</td>
</tr>
<tr>
<td></td>
<td>OR</td>
<td>Measurement Period Start Date</td>
<td>4. OCM Deceased</td>
</tr>
<tr>
<td>4.</td>
<td>Expired within 4 months (120 days) of colon cancer diagnosis</td>
<td>Measurement Period End Date</td>
<td>OCM Colon Cancer Diagnosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NAACCR Item 390</td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NAACCR Item 900</td>
<td>NAACCR Item 1750</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NAACCR Item 960</td>
<td>NAACCR Item 1760</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NAACCR Item 910 Metastatic</td>
<td>OCM Colon Cancer Diagnosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NAACCR Item 900</td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NAACCR Item 970 Metastatic</td>
<td>NAACCR Item 1750</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NAACCR Item 970 In Situ</td>
<td>NAACCR Item 1760</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NAACCR Item 910 In Situ</td>
<td>OCM Clinical Trial Participant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NAACCR Item 970 In Situ</td>
<td>5.</td>
</tr>
<tr>
<td>5.</td>
<td>Participating in clinical trial for colon cancer impacting treatment starts before the start of or during the measurement period and doesn’t end before the start of the measurement period (this is a manual exclusion step and not identified as a NAACCR item)</td>
<td>OCM Deceased</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>OCM Colon Cancer Diagnosis</td>
<td></td>
</tr>
</tbody>
</table>

### Numerator

Chemotherapy is administered within 4 months (120 days) of diagnosis or it is recommended and not received within 4 months (120 days) of diagnosis
### Oncology Care Model Measure Specifications

<table>
<thead>
<tr>
<th>Step(s)</th>
<th>Instructions</th>
<th>Data Element(s)</th>
<th>OCM Code Set(s)</th>
</tr>
</thead>
</table>
| **Step 1** | Note: NAACCR Item # 390 listed below may be used for practice-level aggregate reporting only.  
One of the following options:
1. Chemotherapy is administered within 4 months (120 days) of diagnosis  
   (All of the following FORDS equivalent:
   - NAACCR Item # 1390 Administered  
   - NAACCR Item # 1220  
   - NAACCR Item # 390)  
2. Chemotherapy is recommended and not received within 4 months (120 days) of diagnosis  
   (Both of the following FORDS equivalent:
   - NAACCR Item # 1390 Recommended  
   - NAACCR Item # 390) | • Colon Cancer Diagnosis  
• Colon Cancer Diagnosis Start Date  
• Chemotherapy  
• Chemotherapy Start Date  
• Chemotherapy Recommended  
• Chemotherapy Recommended Start Date  
• NAACCR Item 1390 Administered  
• NAACCR Item 1390 Recommended  
• NAACCR Item 1220  
• NAACCR Item 390 | • OCM Colon Cancer Diagnosis  
• OCM 8 Chemotherapy  
• OCM Chemotherapy Recommended  
OR  
• NAACCR Item 1390 Administered  
• NAACCR Item 1390 Recommended  
• NAACCR Item 1220  
• OCM Colon Cancer Diagnosis  
Additionally, for practice-level aggregate reporting:  
• NAACCR Item 390 |

### Denominator Exceptions
Not Applicable

### Numerator Exclusions
Not Applicable

### Risk Adjustment
None

### Rationale
Improved survival for patients with Stage III lymph node positive colon cancer

### Clinical Recommendation Statements
Not Applicable

### References
Oncology Care Model Measure Specifications


Copyright

This measure is owned by the Commission on Cancer, American College of Surgeons.
Oncology Care Model Measure Specifications

Note: This version of the OCM-8 Measure Flow is to be used for reporting beginning 07/01/2017 and future measurement periods. If an updated version of this document is released, this version will be used for reporting until the effective date of the new version.
Oncology Care Model Measure Specifications

Flowchart:

B

1. Metastatic Disease (AJCC Stage IV)
   - Yes: Denominator Exclusions Met
   - No: Clinical M or Pathologic M

   - Yes: In Situ Disease
     - No: Expired Within 4 Months (120 Days) of Colon Cancer Diagnosis
     - Yes: Participating in Clinical Trial for Colon Cancer Impacting Treatment Starts Before Start of or During and Doesn’t End Before Start of Measurement Period

   - No: Chemotherapy Recommended and Not Received Within 4 Months (120 Days) of Diagnosis
     - Yes: Numerator Met
     - No: Denominator Exclusions Not Met

A

Stop Processing

Numerator Not Met

Denominator Exclusions Met

Numerator Met

No
Please refer to the OCM Measure Specification to identify the data elements and OCM code sets to be used for reporting this measure.

1. For Beneficiary-Level Reporting:
   a. If patient is a Qualifying OCM FFS Beneficiary as Defined in Section 2.1 of the “OCM Clinical Data and Quality Measures Guide,” patient should be reported in the OCM Registry. Proceed to check Patient Age.
   b. If patient is not a Qualifying OCM FFS Beneficiary as Defined in Section 2.1 of the “OCM Clinical Data and Quality Measures Guide,” stop processing. Patient does not qualify as an OCM FFS Beneficiary and patient-level data should not be reported to the OCM Registry.

2. For Aggregate-Level Reporting:
   a. If patient is a Qualifying Practice-Level Patient with “Colon Cancer Diagnosis” Code (see “OCM Tech Spec Value Set” OCM-8 tab), include the patient in aggregate-level totals for reporting to the OCM Registry. Proceed to check Patient Age.
   b. If patient is not a Qualifying Practice-Level Patient with “OCM Colon Cancer Diagnosis” Code (see “OCM Tech Spec Value Set” OCM-8 tab), stop processing. Patient does not qualify as a Practice-Level Patient and should not be included in aggregate-level totals that are reported to the OCM Registry.

3. Check Patient Age:
   a. If Patient Age at Time of Colon Cancer Diagnosis >= 18 Years and <= 79 Years equals No, do not include in Denominator. Stop processing.
   b. If Patient Age at Time of Colon Cancer Diagnosis >= 18 Years and <= 79 Years equals Yes, check Primary Tumors of the Colon.

4. Check Primary Tumors of the Colon:
   a. If Primary Tumors of the Colon Starts During 12 Months Before End of Measurement Period equals No, do not include in Denominator. Stop processing.
   b. If Primary Tumors of the Colon Starts During 12 Months Before End of Measurement Period equals Yes, check Patient Diagnosis of Cancer.

5. Check Patient Diagnosis of Cancer:
   a. If First or Only Cancer Diagnosis equals No, do not include in Denominator. Stop processing.
   b. If First or Only Cancer Diagnosis equals Yes, check Surgical Treatment.

6. Check Surgical Treatment:
Oncology Care Model Measure Specifications

a. If Surgical Treatment of Primary Colon Cancer Site equals No, do not include in Denominator. Stop processing.

b. If Surgical Treatment of Primary Colon Cancer Site equals Yes, check Epithelial Invasive Malignancy Only.

7. Check Epithelial Invasive Malignancy Only:

a. If Epithelial Invasive Malignancy Only equals No, do not include in Denominator. Stop processing.

b. If Epithelial Invasive Malignancy Only equals Yes, check Behavior Code.

8. Check Behavior Code:

a. If Behavior Code = Invasive equals No, do not include in Denominator. Stop processing.

b. If Behavior Code = Invasive equals Yes, check At Least One Regional Lymph Node Positive for Cancer.

9. Check At Least One Regional Lymph Node Positive for Cancer:

a. If At Least One Regional Lymph Node Positive for Cancer (AJCC Stage III) equals No, do not include in Denominator. Stop processing.

b. If At Least One Regional Lymph Node Positive for Cancer (AJCC Stage III) equals Yes, check First Course of Treatment.

10. Check First Course of Treatment:

a. If All or Part of First Course of Treatment Coordinated by Reporting Practice equals No, do not include in Denominator. Stop processing.

b. If All or Part of First Course of Treatment Coordinated by Reporting Practice equals Yes, include in Denominator. Proceed to check Metastatic Disease.

11. Check Metastatic Disease:

a. If Metastatic Disease (AJCC Stage IV) equals Yes, include in Denominator Exclusions. Stop processing.

b. If Metastatic Disease (AJCC Stage IV) equals No, check Clinical M or Pathologic M.

12. Check Clinical M or Pathologic M:

a. If Clinical M or Pathologic M equals Yes, include in Denominator Exclusions. Stop processing.

b. If Clinical M or Pathologic M equals No, check In Situ Disease.
13. Check In Situ Disease:
   a. If In Situ Disease equals Yes, include in Denominator Exclusions. Stop processing.
   b. If In Situ Disease equals No, check Patient Expired.

14. Check Patient Expired:
   a. If Expired Within 4 Months (120 Days) of Colon Cancer Diagnosis equals Yes, include in Denominator Exclusions. Stop processing.
   b. If Expired Within 4 Months (120 Days) of Colon Cancer Diagnosis equals No, check Participating in Clinical Trial.

15. Check Participating in Clinical Trial:
   a. If Participating in Clinical Trial for Colon Cancer Impacting Treatment Starts Before Start of or During and Doesn't End Before Start of Measurement Period equals Yes, include in Denominator Exclusions. Stop processing.
   b. If Participating in Clinical Trial for Colon Cancer Impacting Treatment Starts Before Start of or During and Doesn't End Before Start of Measurement Period equals No, do not include in Denominator Exclusions. Proceed to check Chemotherapy Administered.

16. Check Chemotherapy Administered:
   a. If Chemotherapy Administered Within 4 Months (120 Days) of Diagnosis equals Yes, include in Numerator. Stop processing.
   b. If Chemotherapy Administered Within 4 Months (120 Days) of Diagnosis equals No, check Chemotherapy Recommended and Not Received.

17. Check Chemotherapy Recommended and Not Received:
   a. If Chemotherapy Recommended and Not Received Within 4 Months (120 Days) of Diagnosis equals Yes, include in Numerator. Stop processing.
   b. If Chemotherapy Recommended and Not Received Within 4 Months (120 Days) of Diagnosis equals No, do not include in Numerator. Stop processing.